Endotronix names Chronos as chief medical officer

Peoria, IL, - July 9, 2013 -  Nicolas Chronos, MD has been named Chief Medical Officer for Endotronix.  Dr. Chronos is an interventional cardiologist who is well known for his pioneering research in the treatment of heart disease.  He is an expert in cardiac regenerative medicine, cardiovascular medical device assessment, and translational cardiovascular medicine.

“Dr. Chronos brings experience and understanding of cardiovascular treatments that will greatly benefit Endotronix during a period of tremendous change in healthcare,” said Harry Rowland, Endotronix Chief Executive Officer.  “He will enhance our ability to develop effective devices that improve clinical outcomes while also pioneering the use of innovative mobile technology that assists patients in managing their chronic conditions.”

“My vision is to improve clinical outcomes through safe, effective and innovative care delivery models,” said Dr. Chronos.  “The future of healthcare lies in new paradigms like the Endotronix Care Management Solution which incorporates implantable biosensors, mobile technology, secure IT services, and clinical support.”

Prior to joining Endotronix, Dr. Chronos was CEO of Saint Joseph’s Translational Research Institute in Atlanta, Adjunct Professor at Duke University, and Adjunct Partner at Essex Woodlands Health Ventures.  His distinguished career began with a Degree in Medicine and Surgery from the Royal Free Hospital School of Medicine at the University of London. He trained in cardiology and interventional cardiology at the Royal Brompton National Heart and Lung Institute in London.  Dr. Chronos was awarded a British Heart Foundation International Fellowship and continued his research in interventional cardiology in the United States at Emory University School of Medicine.  

Dr. Chronos is a Consulting Professor of Cardiology and Medicine at Stanford University, and he continues to see patients at Cardiology Care Clinics located near Atlanta in Lake Oconee, Georgia.

About Endotronix

Endotronix (www.endotronix.com) develops digital health solutions with the goal of enhancing the quality of life, improving outcomes, and lowering costs, especially for the 20 million people worldwide who suffer from congestive heart failure.

Endotronix was founded in 2007 by Anthony Nunez, MD and mechanical engineer Harry Rowland, PhD.  The company has a suite of technology patents supporting its innovative care management solutions.  Endotronix is a privately funded company pursuing its CE Mark and European market introduction.          

 

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.